Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors

US9481682B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Ronald Kim · Essen, DE
• Jian Liu · Xi'an, CN
• Xiaolei Gao · Bound Brook, US
• Sobhana Babu Boga · Scotch Plains, US
• Deodialsingh Guiadeen · Linden, US
• Joseph A. Kozlowski · Princeton, US
• Wensheng Yu · Edison, US
• Rajan Anand · Wilmington, US
• Younong Yu · East Brunswick Township, US
• Oleg B. Selyutin · Princeton Colonial Park, US
• Ying-Duo Gao · Murfreesboro, US
• Hao Wu · Shanghai, CN
• Shilan Liu · Shanghai, CN
• Chundao Yang · Shanghai, CN
• Hongjian Wang · 盐官镇, CN

Key dates

• Filing date: Jan 22, 2014
• Grant date: Nov 1, 2016
• Expiry date: Jan 22, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.